Progress in Antidote Against Snake Bites
- NEW YORK – In a meaningful step forward for global health, scientists have developed a novel antivenom with the potential too neutralize the neurotoxins of 19 of the...
- The development stems from an unusual source: Tim Friede, an American snake enthusiast who, over years, built up immunity by gradually injecting himself with increasing doses of snake...
- Researchers from Columbia University and the medical company Centivax collaborated to create the antivenom.
Universal Antivenom Shows Promise Against Deadly Elapid Snakes
Table of Contents
- Universal Antivenom Shows Promise Against Deadly Elapid Snakes
- New Worldwide Antivenom: Hope Against Deadly Snakebites
- 1. What is this new antivenom and what makes it special?
- 2. What are elapid snakes and why are they so hazardous?
- 3. How was this antivenom developed? What was the inspiration behind developing this cure?
- 4.Who were involved in this project?
- 5. How does this new antivenom work?
- 6. How does this antivenom compare to traditional antivenoms?
- 7. What are the results of the animal trials?
- 8. What are the next steps for this antivenom?
- 9. What do experts say about this new antivenom?
- 10. What is the global impact of snakebites, and how could this antivenom help?
- 11. What are the limitations of the antivenom being developed?
Published: 2025-05-03
NEW YORK – In a meaningful step forward for global health, scientists have developed a novel antivenom with the potential too neutralize the neurotoxins of 19 of the world’s deadliest elapid snakes. This breakthrough offers hope for preventing deaths and disabilities caused by snakebites, especially in regions where access to species-specific antivenoms is limited.
Inspired by a Snakebite Survivor
The development stems from an unusual source: Tim Friede, an American snake enthusiast who, over years, built up immunity by gradually injecting himself with increasing doses of snake venom. This ultimately paved the way for groundbreaking medical advancement.
Broad-Spectrum Protection
Researchers from Columbia University and the medical company Centivax collaborated to create the antivenom. According to their report in the journal Cell, the new treatment, composed of three key ingredients, offers protection against the venom of cobras, black mambas, and 17 other elapid species.
Traditional Antivenom Limitations
existing antivenoms typically target only specific snake species, a limitation given that snake venoms are complex cocktails of toxins with varying effects. Traditional antivenoms are produced by injecting horses or sheep with venom and then harvesting the resulting antibodies. Though, these animal-derived antivenoms can cause adverse reactions in humans.
Harnessing Human immunity
Jacob Glanville,head of Centivax and lead author of the study,highlighted the importance of Friede’s ”unique immunologic history.” Over nearly two decades, Friede endured hundreds of bites from 16 highly venomous snake species. His experiences and subsequent survival provided invaluable data.
A Cocktail of Antibodies and Enzyme Inhibitors
From friede’s blood, scientists isolated two potent antibodies – LNX-D09 and SNX-B03 – and combined them with an enzyme inhibitor.This combination forms an active ingredient designed to neutralize a broad range of snake venoms.
Promising Results in Animal Trials
The antivenom cocktail was tested on mice injected with venom from various snake species. The treatment provided complete protection against the venom of 13 species, including king cobras, black mambas, and inland taipans – considered the world’s most venomous snake. It also offered partial protection against six additional species, including the green mamba.
Next Steps: Canine Trials
acknowledging the limitations of mouse studies,the researchers plan to conduct trials on dogs in veterinary clinics that have been bitten by snakes.
Expert Commentary
tim Lüddecke, a biochemist at the University of Gießen not involved in the study, noted that the antivenom’s effectiveness is limited to elapid snakes.The poisons of the vipers, which are completely different and are structured differently, are not addressed,
Lüddecke said. He added that vipers account for a significant proportion of snakebites worldwide. Lüddecke also pointed out that the study primarily focused on survival, while snakebites frequently enough lead to lasting physical disabilities.
Michael Hust from the Technical University of Braunschweig, who also was not involved in the study, said With the cocktail presented in the study from these two antibodies and the enzyme inhibitor, there is a great opportunity to replace animal people who have numerous side effects with a genetically produced product.
A Global Health Imperative
The research team aims to develop universal antivenoms effective against both elapid and viper venoms. They estimate that snakebites cause more than 100,000 deaths and 300,000 permanent disabilities annually, including vision loss and amputations.
New Worldwide Antivenom: Hope Against Deadly Snakebites
Published: 2024-10-27
Snakebites pose a important threat globally, leading to numerous deaths and disabilities each year. But recent advancements in medical research have brought forth an innovative solution. This Q&A-style article delves into a groundbreaking universal antivenom that promises significant progress in combating the effects of venomous snake bites.
1. What is this new antivenom and what makes it special?
This new antivenom is designed to neutralize the neurotoxins of 19 of the world’s deadliest elapid snakes. what sets it apart is its broad-spectrum approach, possibly offering protection against a wide range of snake species, unlike traditional antivenoms that are typically species-specific.This is particularly crucial in regions where access to specialized antivenoms is limited.
2. What are elapid snakes and why are they so hazardous?
Elapid snakes are a family of venomous snakes that includes some of the most deadly species on Earth, such as cobras, mambas, and taipans.These snakes possess potent venoms that ofen contain neurotoxins, which attack the nervous system, leading to paralysis, respiratory failure, and potentially death. Their rapid action and the severity of their effects make elapid snakebites a major public health concern.
3. How was this antivenom developed? What was the inspiration behind developing this cure?
The growth of this antivenom is unique. It originated from the experience of Tim Friede, an American snake enthusiast who, over nearly two decades, built up immunity by injecting himself with increasing doses of snake venom. His body’s immune response to the venom provided invaluable data for the researchers, who were able to isolate and utilize antibodies to create this new treatment. Friede endured hundreds of bites from 16 highly venomous snake species.
4.Who were involved in this project?
This antivenom was a collaborative effort developed by researchers from Columbia University and the medical company Centivax.
5. How does this new antivenom work?
The antivenom is a combination of three key ingredients.Scientists isolated two potent antibodies, LNX-D09 and SNX-B03, from Tim Friede’s blood, and combined them with an enzyme inhibitor. This combination forms an active ingredient, efficiently neutralizing the venom of a broad range of snakes. Specifically, the antibodies bind to the venom, preventing it from attacking the nervous system, while the enzyme inhibitor helps to further mitigate the venom’s effects.
6. How does this antivenom compare to traditional antivenoms?
| Feature | new Antivenom | Traditional Antivenom |
|---|---|---|
| Target Specificity | Broad-spectrum: Targets multiple elapid species | Species-specific: Targets only one or a few snake species |
| Production Method | Utilizes human-derived antibodies combined with an enzyme inhibitor | Produced by injecting horses or sheep with venom, harvesting antibodies |
| Adverse Reactions | potentially lower risk of adverse reactions | Higher risk of adverse reactions in humans |
7. What are the results of the animal trials?
The antivenom cocktail has shown promising results in animal trials. It provided complete protection to mice against the venom of 13 elapid species, including king cobras, black mambas, and inland taipans. It also offered partial protection against six additional species, including the green mamba.
8. What are the next steps for this antivenom?
The researchers plan to conduct trials on dogs in veterinary clinics. These trials are essential to validate the effectiveness of the antivenom in a setting that more closely mirrors human snakebite incidents. This will provide critical data on safety and efficacy before human trials can be considered.
9. What do experts say about this new antivenom?
While not involved in the study, biochemist Tim Lüddecke highlighted that the antivenom’s effectiveness is currently limited to elapid snakes and does not address the poisons from vipers, which constitute a significant portion of snakebites globally. He emphasized that the study primarily focused on survival, leaving long-term disabilities unaddressed. Michael Hust, also not involved in the study, remarked on the chance to replace animal-derived products with a genetically produced product, reducing side effects.
10. What is the global impact of snakebites, and how could this antivenom help?
The research team estimates that snakebites lead to over 100,000 deaths and 300,000 permanent disabilities annually, including vision loss and amputations. A universal antivenom has the potential to considerably reduce these numbers, especially in areas with limited access to species-specific treatments. by providing an accessible and effective treatment, this antivenom offers critical hope in combating the global health crisis caused by snakebites.
11. What are the limitations of the antivenom being developed?
One of the major limitations is that the current formulation is only effective against elapid snakes. It does not provide protection against viper venom,which is responsible for a significant number of snakebites worldwide. Another limitation is the study’s focus on survival, and not addressing the long-term effects of snakebites such as lasting disabilities.